The DECIDE ITN brings together scientists who have made important advances in the fields of haematopoiesis and differentiation therapy and has both scientific and therapeutic targets. DECIDE aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). We will use the information gained to develop ways of alleviating the differentiation block in AML and so deliver new agents, including novel vitamin D and retinoid analogues, for use in differentiation therapy. This type of therapy aims to respond to the urgent need to devise milder treatments, especially for older and frailer AML patients.